is a first-in-class, human immunoglobulin G1 kappa monoclonal antibody that targets the CD38 epitope that is highly expressed on the surface of multiple myeloma cells. In a key clinical trial, monotherapy with intravenous daratumumab in patients with relapsed and refractory multiple myeloma achieved ...
Advances in the treatment of multiple myeloma (MM), particularly the development of immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) and the use of autologous hematopoietic stem cell transplantation, have led to significant improvement in overall survival in patients with MM [1,2]. Nev...
Findings from the phase 3 PERSEUS study found the safety profile of D-VRd in newly diagnosed multiple myeloma to be in line with the known profiles of the agents. Bone marrow aspirate cytology of multiple myeloma: ©David A Litman - stock.adobe.com Findings from the phase 3 PERSEUS ...
参考文献: Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2020 Apr 30; haematol.2019.243790.doi:...
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. PMID: 29231133 Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. PMID: 31936617 Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis. PMID: 35416593 ...
89%的患者对来那度胺耐药,71%的患者对硼替佐米(bortezomib)耐药,64%的患者对硼替佐米和来那度胺耐药。 参考文献: [1]FDA ApprovesDaratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed orRefractory Multiple Myeloma [2]Genmab官网...
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma. PMID: 31936617 Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis. PMID: 35416593 Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. PMID: 33806310 ...
摘要: Daratumumab (Darzalex™) is a first-in-class, human immunoglobulin G1 kappa monoclonal antibody that targets the CD38 epitope that is highly expressed on the surface of multiple myeloma cells. In a key关键词: Multiple Myeloma Bortezomib Lenalidomide Proteasome Inhibitor Overall Response Rate ...
The [daratumumab]-based quadruplet therapy demonstrated a clinically significant reduction in the risk of progression or death for transplant-eligible, newly diagnosed patients with multiple myeloma,” said Craig Tendler, MD, vice president, clinical development, diagnostics, and global medical affairs, ...
(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published in the May 30 issue of the N